trial · primary record
BET Bromodomain Inhibitor ZEN-3694
Recurrent Endometrial Carcinoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 65 |
| Primary completion | 2027-06-30 |
| Primary endpoint | Dose-limiting toxicities (DLTs) (Part I) |
| Registry ID | NCT05950464 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:46.167Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05950464
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.